Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Prospective phase-II study examines survival outcomes in men with metastatic hormone-sensitive prostate cancer after therapy and surgery, indicating potential benefits.
Key Points
Evaluate overall survival and progression-free survival in men with metastatic hormone-sensitive prostate cancer undergoing surgery after combined androgen deprivation therapy.
Conducted a prospective study with 85 patients diagnosed with mHSPC.
Patients received combined androgen deprivation therapy for 6 months followed by cytoreductive prostatectomy and pelvic lymphadenectomy.
Therapeutic response assessed using PSA levels and advanced imaging at 6 months.
Median follow-up was 54.1 months; 3-year overall survival was 94.6%.
Median overall survival was 84 months, median progression-free survival was 72 months.
Complications were observed in 15.3% of patients, with no severe incontinence reported.